Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEAK: PTH (1-84) vs Risedronate in Postmenopausal Osteoporosis
NCT00365456Phase 3Completed
- Sponsor
- Takeda
- Start
- Jul 2006
- Primary completion
- Jan 2011
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of human parathyroid hormone in postmenopausal osteoporosis (2 arms), sponsored by Takeda. Primary endpoint: Change in Lumbar Spine Bone Mineral Density at 12 months. Started Jul 2006; status: completed.
02
Drugs
human parathyroid hormone
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00365456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00365456.